Leukaemia is cancer of the blood-forming cells in the bone marrow. It is not one disease — acute leukaemias require immediate, intensive treatment and can be life-threatening within weeks; chronic leukaemias may be managed long-term with daily oral medication. The South African medical aid experience differs sharply across these types, particularly because of imatinib (Gleevec) — one of the most successful targeted therapies ever developed — and the newer costs of acute leukaemia treatment.
What Is Leukaemia?
Leukaemia is classified by the cell type (myeloid or lymphoid) and the rate of progression (acute or chronic):
Acute Myeloid Leukaemia (AML): Aggressive; requires urgent in-hospital induction chemotherapy. Standard first-line: cytarabine + daunorubicin ("7+3" regimen). Treatment is intensive and hospital-based. Bone marrow transplant (allogeneic) is consolidation therapy for high-risk or relapsed cases.
Acute Lymphoblastic Leukaemia (ALL): More common in children than adults; SA paediatric ALL has among the lowest cure rates globally in the public sector due to access barriers, but in the private sector, modern protocols achieve 80–90% cure rates in children. Adult ALL is more aggressive. Multi-drug chemotherapy (hyper-CVAD or similar) over 2+ years.
Chronic Myeloid Leukaemia (CML): Defined by the Philadelphia chromosome (BCR-ABL fusion gene). Treated with oral tyrosine kinase inhibitors (TKIs) — imatinib (generic now available), dasatinib, nilotinib, bosutinib. CML on imatinib is a chronic, manageable condition — many patients live normal lifespans. This is the most prevalent leukaemia type in adult SA patients on chronic treatment.
Chronic Lymphocytic Leukaemia (CLL): Most common leukaemia in older adults. Often watch-and-wait initially. Treatment when progressing: BTK inhibitors (ibrutinib, acalabrutinib), venetoclax ± obinutuzumab.
How Common Is Leukaemia in South Africa?
The National Cancer Registry confirms leukaemia in both sexes across all age groups. CML is the most common adult leukaemia presenting to private-sector haematologists. ALL is predominantly paediatric. AML peaks in older adults (60+). CLL is predominantly in patients over 60.
Is Leukaemia a PMB Condition?
Yes. All leukaemia types are covered under the Prescribed Minimum Benefits as Level 1 oncological conditions. All registered schemes must fund:
- Diagnosis: Full blood count (FBC), peripheral blood film, bone marrow aspirate and trephine biopsy, cytogenetics (FISH for BCR-ABL in CML), flow cytometry.
- Acute leukaemia treatment: In-hospital induction chemotherapy, consolidation chemotherapy, supportive care (blood products, antimicrobials, growth factors).
- Allogeneic bone marrow transplant: Covered under PMB as consolidation therapy for qualifying AML/ALL patients (at designated transplant centres).
- CML first-line TKI (imatinib): Imatinib is generally classified as the PMB minimum treatment for CML. Both originator (Gleevec, now largely superseded by generic) and generic imatinib are available in SA at significantly different costs.
The imatinib cost story: Generic imatinib in South Africa costs approximately R3,000–R8,000 per month; the originator product Gleevec was historically R20,000–R30,000/month before generic entry. Most schemes now fund generic imatinib as first-line PMB treatment for CML. Second-generation TKIs (dasatinib, nilotinib) require exceptional-needs authorisation in most SA schemes.
How Does Medical Aid Cover Leukaemia?
| Treatment | PMB Status | Notes |
|---|---|---|
| Diagnosis (FBC, BMA, cytogenetics, flow cytometry) | Yes — PMB | |
| AML induction: cytarabine + daunorubicin | Yes — PMB minimum standard | In-hospital; high-cost per admission |
| ALL: multi-drug chemotherapy protocols | Yes — PMB | Over 2+ years with maintenance |
| CML first-line: imatinib (generic) | Yes — PMB | Generic is generally the PMB minimum |
| CML: dasatinib / nilotinib (2nd gen TKI) | Exceptional needs | Indicated if imatinib intolerant or resistant |
| CML: ponatinib / asciminib (3rd gen TKI) | Exceptional needs | Rare T315I mutation or 3rd-line |
| CLL: ibrutinib / acalabrutinib (BTK inhibitors) | Exceptional needs in most schemes | R20,000–R40,000/month |
| CLL: venetoclax | Exceptional needs | |
| Allogeneic bone marrow transplant | PMB for qualifying patients | At designated transplant centres only |
| Autologous stem cell transplant (ALL consolidation) | PMB for qualifying patients | |
| Intrathecal chemotherapy (ALL CNS prophylaxis) | Yes — PMB |
Day-to-Day Costs: What to Budget For
Chronic Myeloid Leukaemia (CML):
| Scenario | Estimated Annual Cost |
|---|---|
| CML, generic imatinib (first-line) | R40,000 – R100,000 |
| CML, dasatinib / nilotinib (exceptional needs) | R200,000 – R400,000 |
| CML, monitoring (PCR for BCR-ABL, haematologist visits) | R15,000 – R30,000/year additional |
Acute Myeloid Leukaemia (AML):
| Scenario | Estimated Annual Cost |
|---|---|
| AML induction + consolidation (without transplant) | R250,000 – R500,000 |
| AML + allogeneic bone marrow transplant | R500,000 – R900,000 [NEEDS VERIFICATION] |
Chronic Lymphocytic Leukaemia (CLL):
| Scenario | Estimated Annual Cost |
|---|---|
| CLL, watch and wait (monitoring only) | R10,000 – R25,000 |
| CLL, ibrutinib (exceptional needs) | R250,000 – R500,000 |
| CLL, venetoclax ± obinutuzumab | R300,000 – R600,000 |
Gap Cover Relevance
Gap cover is relevant for leukaemia at several points: - Haematologist consultations: Specialist shortfalls on ongoing consultations (every 1–3 months for CML; more frequent for acute leukaemia). - Hospital admissions (AML/ALL induction): Intensive chemotherapy in hospital generates significant specialist and facility shortfalls. - Bone marrow trephine biopsy and other procedures: Procedure shortfalls. - Bone marrow transplant: Specialist shortfalls at the transplant centre.
For CML patients on long-term oral imatinib, gap cover is less relevant (no hospital admissions once stable) — the ongoing cost is the TKI medication itself, which is funded as a chronic/PMB benefit.
Key Questions to Ask Your Scheme
- Is generic imatinib covered as PMB for CML? And at what monthly cost?
- If imatinib fails or causes intolerance, what is the exceptional-needs process for dasatinib or nilotinib?
- Is allogeneic bone marrow transplant covered, and at which DSP facilities?
- What is my oncology sub-limit? For acute leukaemia, hospital treatment can exhaust a low sub-limit within one or two admissions.
- Does the scheme fund PCR monitoring tests (BCR-ABL quantitative PCR) for CML surveillance? These are essential for treatment monitoring and cost R2,000–R5,000 per test.
Talk to Eldon
CML patients face a long-term annual medication cost; acute leukaemia patients face intensive short-term hospital costs. The Check shows what each plan on our panel pays for this, side by side, and Eldon advises from there.
See which plans pay for leukaemia cover →